Restarting Aspirin After Non-Bleeding Duodenal Ulcer

Timing of Aspirin Resumption

The American College of Cardiology recommends that aspirin therapy should be restarted immediately or as soon as possible after diagnosis in patients with a non-bleeding duodenal ulcer who require aspirin for cardiovascular protection, while simultaneously initiating proton pump inhibitor (PPI) therapy 1, 2, 3
In patients who require low-dose aspirin for cardiovascular protection, no aspirin-free period should be mandated; instead, aspirin should be restarted as soon as the risk for cardiovascular complications is thought to outweigh the risk for bleeding, with a strength of evidence supported by multiple studies 1, 3
Discontinuation of aspirin therapy is associated with a 3-fold higher risk of major adverse cardiac events, with thrombotic events typically occurring between 7-10 days after discontinuation, highlighting the importance of prompt aspirin resumption 1, 3
A randomized controlled trial found that immediate reintroduction of aspirin with PPI therapy resulted in a 10-fold lower all-cause mortality compared to discontinuing aspirin (1.3% vs 12.9%), despite a numerically higher but non-significant rebleeding rate, demonstrating the benefits of early aspirin resumption 2, 5

Always initiate a PPI concurrently when restarting aspirin to reduce the risk of ulcer complications, as recommended by the American Gastroenterological Association 1, 3, 6
For non-bleeding ulcers with clean base, the risk of rebleeding with aspirin plus PPI is significantly lower than the cardiovascular risk of discontinuing aspirin, with a strength of evidence supported by multiple studies 2, 4
The combination of aspirin with a PPI has been shown to be superior to clopidogrel alone for preventing recurrent bleeding (OR 0.06), highlighting the importance of concurrent PPI therapy 1, 7

For patients with recent coronary stents on dual antiplatelet therapy (DAPT), consult with a cardiologist before making any changes to the antiplatelet regimen, as recommended by the American Heart Association 8, 4
If the patient is on DAPT and has a high risk of stent thrombosis, consider continuing aspirin while temporarily withholding the P2Y12 inhibitor (e.g., clopidogrel), with a strength of evidence supported by multiple studies 2, 8
P2Y12 receptor inhibitors should be restarted within 5 days after endoscopic diagnosis if they were temporarily discontinued, as recommended by the European Society of Cardiology 8, 4

Assess cardiovascular risk and indication for aspirin therapy: for secondary prevention (established cardiovascular disease), restart aspirin immediately, as recommended by the American College of Cardiology 1, 4
Initiate PPI therapy at standard healing dose: for duodenal ulcers, typically 4-6 weeks of PPI therapy is sufficient for healing, with a strength of evidence supported by multiple studies 9

Unnecessarily delaying aspirin resumption increases thrombotic risk, which can lead to higher mortality than the risk of ulcer rebleeding, highlighting the importance of prompt aspirin resumption 2, 3
Failing to provide concurrent PPI therapy when restarting aspirin significantly increases rebleeding risk, with a strength of evidence supported by multiple studies 1, 7
Discontinuing both antiplatelet agents simultaneously in patients on DAPT can lead to stent thrombosis in as little as 7 days, highlighting the importance of careful management of antiplatelet therapy 8, 5